Royalty Pharma (RPRX) Set to Release Earnings on Wednesday

Royalty Pharma (NASDAQ:RPRX) is expected to be releasing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of $1.18 per share and revenue of $884.84 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.05. The business had revenue of $674.14 million during the quarter, compared to analysts’ expectations of $758.93 million. Royalty Pharma had a net margin of 32.14% and a return on equity of 30.01%. On average, analysts expect Royalty Pharma to post $5.29 EPS for the current fiscal year and $5.64 EPS for the next fiscal year.

Royalty Pharma Trading Down 1.0%

NASDAQ RPRX opened at $66.52 on Tuesday. The firm’s fifty day moving average price is $60.38 and its 200 day moving average price is $53.26. Royalty Pharma has a 12 month low of $36.03 and a 12 month high of $67.71. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80. The company has a market capitalization of $38.25 billion, a price-to-earnings ratio of 45.88, a price-to-earnings-growth ratio of 1.78 and a beta of 0.42.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a $0.2350 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $0.94 dividend on an annualized basis and a yield of 1.4%. Royalty Pharma’s payout ratio is 64.83%.

Insider Activity at Royalty Pharma

In other Royalty Pharma news, EVP Christopher Hite sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total transaction of $5,853,000.00. Following the completion of the sale, the executive vice president directly owned 270,401 shares of the company’s stock, valued at $15,826,570.53. This represents a 27.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of the stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $57.10, for a total value of $235,594.60. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 208,252 shares of company stock valued at $12,324,407. 18.84% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Bank of America reaffirmed a “buy” rating on shares of Royalty Pharma in a report on Wednesday, August 5th. JPMorgan Chase & Co. boosted their target price on Royalty Pharma from $58.00 to $62.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Morgan Stanley upped their target price on Royalty Pharma from $65.00 to $67.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. The Goldman Sachs Group reissued a “buy” rating and issued a $66.00 target price on shares of Royalty Pharma in a research report on Thursday, August 6th. Finally, Wall Street Zen downgraded Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 26th. Eight analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $61.57.

Royalty Pharma Company Profile

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.